These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 33946045)
1. The prognostic and immunological effects of ZBTB7C across cancers: friend or foe? Chen X; Jiang Z; Wang Z; Jiang Z Aging (Albany NY); 2021 May; 13(9):12849-12864. PubMed ID: 33946045 [TBL] [Abstract][Full Text] [Related]
2. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker. Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W Front Immunol; 2021; 12():646523. PubMed ID: 33679809 [TBL] [Abstract][Full Text] [Related]
3. Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer. Jiang AM; Ren MD; Liu N; Gao H; Wang JJ; Zheng XQ; Fu X; Liang X; Ruan ZP; Tian T; Yao Y Int J Med Sci; 2021; 18(1):226-238. PubMed ID: 33390791 [No Abstract] [Full Text] [Related]
4. Prognostic value and immunological role of PDCD1 gene in pan-cancer. Miao Y; Wang J; Li Q; Quan W; Wang Y; Li C; Wu J; Mi D Int Immunopharmacol; 2020 Dec; 89(Pt B):107080. PubMed ID: 33069926 [TBL] [Abstract][Full Text] [Related]
5. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
6. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers. Wang N; Zhu L; Wang L; Shen Z; Huang X Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736 [TBL] [Abstract][Full Text] [Related]
7. Elucidating the pan-oncologic landscape of S100A9: prognostic and therapeutic corollaries from an integrative bioinformatics and Mendelian randomization analysis. Chen Y; Wu Z; Yi X Sci Rep; 2024 Aug; 14(1):19071. PubMed ID: 39154046 [TBL] [Abstract][Full Text] [Related]
8. DEPDC1B: A novel tumor suppressor gene associated with immune infiltration in colon adenocarcinoma. Zhu D; Feng H; Zhang Z; Li J; Li Y; Hou T Cancer Med; 2024 Aug; 13(15):e70043. PubMed ID: 39087856 [TBL] [Abstract][Full Text] [Related]
9. Analysis of the Expression and Prognostic Value of MSH2 in Pan-Cancer Based on Bioinformatics. Qiu W; Ding K; Liao L; Ling Y; Luo X; Wang J Biomed Res Int; 2021; 2021():9485273. PubMed ID: 34859104 [TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2. Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y Front Immunol; 2023; 14():1155182. PubMed ID: 37275857 [TBL] [Abstract][Full Text] [Related]
11. Exploration of the relationship between tumor mutation burden and immune infiltrates in colon adenocarcinoma. Ouyang R; Li Z; Peng P; Zhang J; Liu J; Qin M; Huang J Int J Med Sci; 2021; 18(3):685-694. PubMed ID: 33437203 [No Abstract] [Full Text] [Related]
12. Identification of ANXA1 as a potential prognostic biomarker and correlating with immune infiltrates in colorectal cancer. Liang Z; Li X Autoimmunity; 2021 Mar; 54(2):76-87. PubMed ID: 33596760 [TBL] [Abstract][Full Text] [Related]
13. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer. Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444 [TBL] [Abstract][Full Text] [Related]
14. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer. Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J Front Immunol; 2021; 12():812713. PubMed ID: 35069601 [TBL] [Abstract][Full Text] [Related]
15. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687 [TBL] [Abstract][Full Text] [Related]
16. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database. Liu J; Xu W; Li S; Sun R; Cheng W Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439 [No Abstract] [Full Text] [Related]
17. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer. Lin A; Zhang J; Luo P Front Immunol; 2020; 11():2039. PubMed ID: 32903444 [TBL] [Abstract][Full Text] [Related]
18. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study. Zhang L; Li B; Peng Y; Wu F; Li Q; Lin Z; Xie S; Xiao L; Lin X; Ou Z; Cai T; Rong H; Fan S; Li J Oral Oncol; 2020 Nov; 110():104943. PubMed ID: 32919362 [TBL] [Abstract][Full Text] [Related]
19. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer. Luo C; Chen J; Chen L Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155 [TBL] [Abstract][Full Text] [Related]
20. The Potential Impact of HNRNPA2B1 on Human Cancers Prognosis and Immune Microenvironment. Huang T; Zhu G; Chen F J Immunol Res; 2024; 2024():5515307. PubMed ID: 39268079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]